Corza Medical GmbH - search results

European Union - English - EMA (European Medicines Agency)

tachosil

corza medical gmbh - human fibrinogen, human thrombin - hemostasis, surgical - antihemorrhagics - tachosil is indicated in adults and children from 1 month of age for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient. tachosil is indicated in adults for supportive sealing of the dura mater to prevent postoperative cerebrospinal leakage following neurological surgery (see section 5.1).

Canada - English - Health Canada

tachosil patch

corza medical gmbh - thrombin (human); collagen; fibrinogen (human) - patch - 2unit; 2.1mg; 5.5mg - thrombin (human) 2unit; collagen 2.1mg; fibrinogen (human) 5.5mg - hemostatics

Canada - English - Health Canada

tachosil patch

corza medical gmbh - thrombin (human); collagen; fibrinogen (human) - patch - 2unit; 2.1mg; 5.5mg - thrombin (human) 2unit; collagen 2.1mg; fibrinogen (human) 5.5mg - hemostatics

Canada - English - Health Canada

tachosil patch

corza medical gmbh - fibrinogen (human); thrombin (human); collagen - patch - 5.5mg; 2unit; 2.1mg - fibrinogen (human) 5.5mg; thrombin (human) 2unit; collagen 2.1mg - hemostatics

United States - English - NLM (National Library of Medicine)

tachosil- thrombin human and fibrinogen patch

corza medical gmbh - human thrombin (unii: 6k15abl77g) (human thrombin - unii:6k15abl77g), fibrinogen human (unii: n94833051k) (fibrinogen human - unii:n94833051k) - tachosil is a fibrin sealant patch indicated for use with manual compression in adult and pediatric patients as an adjunct to hemostasis in cardiovascular and hepatic surgery when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical. limitations for use do not use tachosil for: risk summary a review of available data suggests that major birth defects occur in 2-4% of the u.s. general population and that miscarriage occurs in 15-20% of clinically recognized pregnancies, regardless of drug exposure. animal reproduction studies have not been conducted with tachosil. there are no adequate and well-controlled studies in pregnant women. it is also not known whether tachosil can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. tachosil should be administered to pregnant women only if clearly needed. it is not known whether this drug is excreted in human milk. because many drugs are excreted in human milk, ca